---
title: "Jiangsu Hengrui Appoints Zhang Wei as Senior Vice President"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304084639.md"
description: "Jiangsu Hengrui Medicine Co. Ltd. has appointed Zhang Wei as Senior Vice President, effective November 3, 2026, for the remainder of the current board's term. Zhang brings over 20 years of global drug development leadership experience and previously served as Senior Vice President and Head of Medicine for Greater China at Boehringer Ingelheim."
datetime: "2026-11-03T09:04:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304084639.md)
  - [en](https://longbridge.com/en/news/304084639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304084639.md)
generator: "portal-rs"
---

# Jiangsu Hengrui Appoints Zhang Wei as Senior Vice President

-   Jiangsu Hengrui appointed Zhang Wei senior vice president, effective November 3, 2026, through the end of the current board’s term. \* Zhang previously served as senior vice president and head of medicine for Greater China at Boehringer Ingelheim. \* He has more than 20 years of global drug development leadership experience. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261103-12397119), on November 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Hengrui Announces Drug Inclusions in China’s 2026 NRDL](https://longbridge.com/en/news/305570916.md)
- [Hengrui presenta investigaciones innovadoras en el Congreso ESMO 2026](https://longbridge.com/en/news/303511755.md)
- [Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals](https://longbridge.com/en/news/303205414.md)
- [Jiangsu Hengrui Files HKEX Next Day Disclosure Return Announcing Share Buyback](https://longbridge.com/en/news/302695857.md)
- [Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value](https://longbridge.com/en/news/302491193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**